Douglas Earl Martin 4
4 · Allogene Therapeutics, Inc. · Filed Jan 28, 2025
Insider Transaction Report
Form 4
Douglas Earl Martin
SVP, General Counsel
Transactions
- Award
Stock Option (Right to buy)
2025-01-24+512,370→ 512,370 totalExercise: $1.94Exp: 2035-01-24→ Common Stock (512,370 underlying) - Award
Common Stock
2025-01-24+144,928→ 594,252 total
Footnotes (1)
- [F1]25% of the shares subject to the stock option shall vest on January 24, 2026, and the remaining shares shall vest in 36 equal monthly installments thereafter.